Ovarian Cancer – Cell and Gene Therapies 15-Market Assessment and Forecast to 2031

Ovarian Cancer Cell and Gene Therapy Market Report Overview

Ovarian cancer can be broken down into many different types of neoplasms based on specific histopathologic entities and clinical behaviors, and treatment depends on the specific tumor type. Most clinical cases are epithelial ovarian cancers, which represent approximately 90% of diagnosed patients.

Ovarian Cancer cell and gene therapy (CGT) market research includes an assessment of the disease epidemiology and 10-year patient-based forecast (PBF) across the 8MM for marketed and pipeline therapies with established mechanisms of action and cell & gene therapies by class, including early to late clinical-stage pipeline products, with a launch date assessment by market for ovarian cancer. In addition to PBF sales data for the 8MM, this report contains sales forecast extrapolations for an additional seven geographical markets (7M), totaling 15 markets (15M). These sales forecast extrapolations leverage data on pharmaceutical sales and drug availability from GlobalData’s World Markets Healthcare (WMH) and POLI Price Intelligence databases.

Ovarian Cancer Cell and Gene Therapy Market Drivers

Some of the key factors driving the Ovarian Cancer cell and gene therapy market are:

• Increasing number of ovarian cancer cases throughout the forecast period.
• Approval and launch of premium-priced therapeutics.
• High level of unmet need in patients resistant to platinum, especially in the third and fourth lines of therapy.

Ovarian Cancer Cell and Gene Therapy Market Unmet Needs

Ovarian cancer presents with unmet needs that are yet to be addressed sufficiently to date, current treatment options cannot overcome acquired resistance to platinum-based chemotherapy, which appears as a big area of unmet need for drug developers to address. There is a limited number of late-stage pipeline CGT agents that target platinum-refractory and resistant patient populations and those currently in clinical trials have yet to demonstrate efficacy in this setting, however this is the ideal ground for CGTs to be a commercial success. The historic difficulties experienced by developers who approached this patient segment with platinum resistant disease casts doubt over the prospects for these patients. However, it is expected that CGTs can provide a novel individualized therapy option which is also an unmet need in ovarian cancer.

To know more about the unmet needs in the Ovarian Cancer market,  download a free report sample

Ovarian Cancer Cell and Gene Therapy Market Segmentation by Regions

The key regions in the Ovarian Cancer cell and gene therapy market are North America, APAC, Europe, and the Middle East. North America held the highest market share in 2021.

Ovarian Cancer Cell and Gene Therapy Market Analysis by Regions, 2021 (%)

For more regional insights on the Ovarian Cancer cell and gene therapy market, download a free report sample

Ovarian Cancer Cell and Gene Therapy Market – Competitive Landscape

Some of the future players in the Ovarian Cancer cell and gene therapy market are Triumvira Immunologics, Adaptimmune Therapeutics; ICON, Gradalis, TScan Therapeutics, Poseida Therapeutics; Sarah Cannon Research Institute, Instil Bio, Imunon; WCG Clinical, GOG Foundation; NanoCarrier; Vascular Biogenics, Imunon, Adaptimmune Therapeutics; GOG Foundation, and Gradalis. Imunon is the number one sponsoring company for CGT trials in ovarian cancer, followed by Adaptimmune Therapeutics and AiVita Biomedical.

Ovarian Cancer Cell and Gene Therapy Market, by Competitors

For more insights on companies in the Ovarian Cancer cell and gene therapy market,  download a free report sample

Segments Covered in the Report

Ovarian Cancer Cell and Gene Therapy Market Regions Outlook (Value, $Billion, 2021-2031)

• North America
• APAC
• Europe
• The Middle East
• Africa

Scope

Ovarian Cancer cell and gene therapy market research includes an assessment of the disease epidemiology and 10-year patient-based forecast (PBF) across the 8MM for marketed and pipeline therapies with established mechanisms of action and cell & gene therapies by class, including early to late clinical-stage pipeline products, with a launch date assessment by market for ovarian cancer. In addition to PBF sales data for the 8MM, this report contains sales forecast extrapolations for an additional seven geographical markets (7M), totaling 15 markets (15M). These sales forecast extrapolations leverage data on pharmaceutical sales and drug availability from GlobalData’s World Markets Healthcare (WMH) and POLI Price Intelligence databases.

Key Highlights

Report deliverables include a PowerPoint report and Excel-based forecast model

Forecast includes 8 countries

Forecast covers 2021-2031

Seven markets are extrapolated, obtaining a 15-market value for all Ovarian Cancer therapeutics

Reasons to Buy

• Obtain cell & gene therapy sales forecasts across multiple regions
• Gain insight into promising early-stage approaches

Our indication specific forecast models answer questions such as:

• What is the target patient pool for cell & gene therapies in each cancer indication?
• Which patient groups are more likely to receive these therapies?
• What does the cell & gene therapy clinical stage pipeline look like in each cancer indication
• What is the anticipated breakdown between autologous and allogeneic cell therapies?
• When will cell & gene therapies launch in each market?
• What is the total market value projected for the forecast end, in 2031?